Uniqure NV
QURE30.840USD
+4.690+17.93%
收盘 11/11, 16:00（美东）报价延迟15分钟
1.92B总市值
亏损市盈率 TTM
关于 Uniqure NV 公司
Uniqure NV 是一家总部位于荷兰的基因治疗公司。该公司致力于开发一次性给药的治疗方法，为患有遗传性疾病和其他毁灭性疾病的患者提供潜在的治愈效果。该公司通过内部和合作伙伴开发了一系列基因疗法。该公司在自己的工厂中生产基于腺相关病毒（或 AAV）的基因疗法，采用专有的、商业规模的、符合现行良好生产规范的制造工艺。AMT-061 是该公司针对血友病 B 患者的主要候选产品，目前正在进行关键研究的给药阶段。AMT-130 是针对亨廷顿氏病患者的候选产品，目前正处于 I/II 期临床研究阶段。
Uniqure NV简介
公司代码QURE
公司名称Uniqure NV
上市日期Feb 05, 2014
CEOMr. Matthew (Matt) Kapusta, CPA
员工数量209
证券类型Ordinary Share
年结日Feb 05
公司地址Paasheuvelweg 25a
城市AMSTERDAM
上市交易所NASDAQ Global Select Consolidated
国家Netherlands
邮编1105 BP
电话31202406000
网址https://www.uniqure.com/
公司代码QURE
上市日期Feb 05, 2014
CEOMr. Matthew (Matt) Kapusta, CPA
Uniqure NV公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
--
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
32.06K
-32.72%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
20.27K
+40.66%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
15.67K
-22.96%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
--
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
32.06K
-32.72%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 11月8日 周六
更新时间: 11月8日 周六
持股股东
股东类型
持股股东
持股股东
占比
RTW Investments L.P.
8.28%
EcoR1 Capital, LLC
6.40%
Vestal Point Capital, LP
5.94%
Avoro Capital Advisors LLC
5.82%
abrdn Inc.
4.72%
其他
68.84%
持股股东
持股股东
占比
RTW Investments L.P.
8.28%
EcoR1 Capital, LLC
6.40%
Vestal Point Capital, LP
5.94%
Avoro Capital Advisors LLC
5.82%
abrdn Inc.
4.72%
其他
68.84%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
45.59%
Hedge Fund
18.44%
Investment Advisor
14.82%
Research Firm
6.51%
Corporation
3.88%
Venture Capital
3.21%
Individual Investor
1.50%
Private Equity
0.98%
Bank and Trust
0.24%
其他
4.83%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
368
55.15M
89.53%
-7.50M
2025Q2
396
55.26M
101.06%
-1.58M
2025Q1
429
55.29M
101.00%
-4.83M
2024Q4
431
46.57M
86.23%
-10.92M
2024Q3
431
43.93M
89.29%
-10.96M
2024Q2
435
37.07M
76.08%
-15.19M
2024Q1
449
38.56M
80.27%
-17.69M
2023Q4
454
43.54M
90.77%
-8.61M
2023Q3
462
41.52M
86.64%
-16.34M
2023Q2
452
41.43M
87.10%
-18.53M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RTW Investments L.P.
5.16M
8.37%
+892.80K
+20.93%
Jun 30, 2025
EcoR1 Capital, LLC
3.99M
6.48%
--
--
Jun 30, 2025
Vestal Point Capital, LP
3.70M
6.01%
-1.09M
-22.80%
Jun 30, 2025
Avoro Capital Advisors LLC
3.63M
5.88%
+1.45M
+66.67%
Jun 30, 2025
abrdn Inc.
2.75M
4.47%
+535.16K
+24.15%
Jun 30, 2025
Bristol Myers Squibb
2.39M
3.88%
--
--
Sep 30, 2024
Jefferies LLC
2.10M
3.4%
+2.10M
--
Jun 30, 2025
Nantahala Capital Management, LLC
2.05M
3.33%
-704.11K
-25.55%
Jun 30, 2025
Franklin Advisers, Inc.
1.61M
2.61%
-382.31K
-19.23%
Jun 30, 2025
Two Sigma Investments, LP
1.60M
2.6%
+15.67K
+0.99%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
WisdomTree BioRevolution Fund
4.09%
Global X Genomics & Biotechnology ETF
3.36%
Virtus LifeSci Biotech Clinical Trials ETF
2.63%
Invesco NASDAQ Future Gen 200 ETF
1.73%
SPDR S&P Biotech ETF
1.24%
Alger Mid Cap 40 ETF
1.07%
Tema Heart & Health ETF
0.73%
Direxion Daily S&P Biotech Bull 3X Shares
0.65%
Harbor Health Care ETF
0.6%
Invesco Nasdaq Biotechnology ETF
0.34%
查看更多
WisdomTree BioRevolution Fund
占比4.09%
Global X Genomics & Biotechnology ETF
占比3.36%
Virtus LifeSci Biotech Clinical Trials ETF
占比2.63%
Invesco NASDAQ Future Gen 200 ETF
占比1.73%
SPDR S&P Biotech ETF
占比1.24%
Alger Mid Cap 40 ETF
占比1.07%
Tema Heart & Health ETF
占比0.73%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.65%
Harbor Health Care ETF
占比0.6%
Invesco Nasdaq Biotechnology ETF
占比0.34%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
